Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China.

Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China.

<h4>Objective</h4>We aimed to investigate the cost-effectiveness of tislelizumab plus chemotherapy compared to chemotherapy alone as a first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (OSCC).<h4>Methods</h4>A partitioned survival model was d...

Full description

Saved in:
Bibliographic Details
Main Authors: Chaoneng He, Xiufang Mi, Gaoqi Xu, Xinglu Xu, Wenxiu Xin, Like Zhong, Junfeng Zhu, Qi Shu, Luo Fang, Haiying Ding
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2024-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0302961&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items